Ocular Therapeutix (OCUL)
(Delayed Data from NSDQ)
$4.20 USD
-0.45 (-9.58%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $4.20 0.00 (0.00%) 6:18 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Cash flow Statements
Fiscal Year End for Ocular Therapeutix, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -80.74 | -71.04 | -6.55 | -155.64 | -86.37 |
Depreciation/Amortization & Depletion | 2.98 | 2.11 | 2.42 | 2.77 | 2.53 |
Net Change from Assets/Liabilities | -7.41 | 1.35 | -2.90 | 1.18 | -1.88 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 14.93 | 7.98 | -58.52 | 98.13 | 8.14 |
Net Cash From Operating Activities | -70.23 | -59.60 | -65.55 | -53.55 | -77.58 |
Property & Equipment | -6.09 | -3.72 | -1.19 | -0.84 | -2.24 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -6.09 | -3.72 | -1.19 | -0.84 | -2.24 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 118.66 | 1.45 | 3.57 | 228.01 | 38.07 |
Issuance (Repayment) of Debt | 56.35 | 0.00 | -0.44 | 0.00 | 37.28 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -5.18 | 0.00 | -0.28 | 0.00 | 0.00 |
Net Cash from Financing Activities | 169.83 | 1.45 | 2.85 | 228.01 | 75.34 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 93.51 | -61.86 | -63.89 | 173.62 | -4.48 |
Cash at Beginning of Period | 104.06 | 165.93 | 229.82 | 56.20 | 60.68 |
Cash at End of Period | 197.57 | 104.06 | 165.93 | 229.82 | 56.20 |
Diluted Net EPS | -1.02 | -0.97 | -0.98 | -2.56 | -1.91 |
Fiscal Year End for Ocular Therapeutix, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -80.74 | -51.52 | -51.00 | -30.32 |
Depreciation/Amortization & Depletion | NA | 2.98 | 2.03 | 1.14 | 0.48 |
Net Change from Assets/Liabilities | NA | -7.41 | -0.86 | -7.08 | -2.50 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 14.93 | 2.57 | 16.90 | 12.36 |
Net Cash From Operating Activities | NA | -70.23 | -47.78 | -40.05 | -19.97 |
Property & Equipment | NA | -6.09 | -5.63 | -5.37 | -3.38 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -6.09 | -5.63 | -5.37 | -3.38 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 118.66 | 10.49 | 9.72 | 0.08 |
Issuance (Repayment) of Debt | NA | 56.35 | 56.35 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -5.18 | -5.18 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 169.83 | 61.66 | 9.72 | 0.08 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 93.51 | 8.25 | -35.69 | -23.27 |
Cash at Beginning of Period | NA | 104.06 | 104.06 | 104.06 | 104.06 |
Cash at End of Period | NA | 197.57 | 112.31 | 68.37 | 80.79 |
Diluted Net EPS | NA | -0.12 | -0.25 | -0.26 | -0.39 |